ReconTop Stories

Smith+Nephew expands procedural innovation with introduction of JOURNEY™ II ROX™ Total Knee Solution

LONDON, Nov. 1, 2022 /PRNewswire/ — Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of its JOURNEY II ROX Total Knee Solution – a reverse hybrid construct for total knee arthroplasty. This new procedural product solution aims to provide surgeons with the clinical advantage of an advanced bearing material and anatomic design combined with the efficiencyand potential long-term tibia fixation of a cementless knee.

The JOURNEY II ROX Total Knee Solution combines several of Smith+Nephew’s high performance technologies in one construct – the characteristic kinematics2-8 of JOURNEY II TKA, the clinical history*9,10 of CONCELOC Advanced Porous Titanium and the wear resistance of OXINIUM Oxidized Zirconium.11-13 The JOURNEY II ROX Total Knee Solution is also compatible with Smith+Nephew’s CORI Surgical System enabling surgeons to perform the procedure using next generation robotics-assisted technology.

“The reverse hybrid combination provides my patients with a powerful collection of knee arthroplasty technologies. The kinematic functionality of JOURNEY II, the biocompatibility and longevity benefits of an oxidized zirconium alloy femoral component in OXINIUM and now CONCELOC,” said Dr. Steven B. Haas, Chief, the Knee Service and John N. Insall Chair, Knee Surgery at the Hospital for Special Surgery in New York. “CONCELOC offers the potential to achieve osseointegration where it is needed – the tibia and patellae. It’s an evidence-based approach to knee arthroplasty that utilizes high performance technologies delivered with the operative time savings recognized in a complete cementless procedure.”

“The reverse hybrid technique works very well in my hands and I’m able to ensure my patients have the opportunity to harness the JOURNEY II knee mechanics for a more natural knee function,” said Dr. Matthew Bullock, Associate Professor of Orthopaedic Surgery, Marshall University, Joan C. Edwards School of Medicine. “The hybrid approach does not add time to my cases – in fact, I find that using the porous tibia and patella components reduces my operative time by approximately 15 minutes instead of waiting for cement to cure.”

“Driving procedural innovation to help surgeons treat patients and provide better outcomes is the core of our purpose – Life Unlimited,” said Randy Kilburn, Executive Vice President and General Manager, Global Joint Reconstruction and Robotics at Smith+Nephew. “The JOURNEY II ROX Total Knee Solution underscores this by bringing together high performance components to deliver a custom procedural solution that no other company offers.”

Smith+Nephew will preview the JOURNEY II ROX Total Knee Solution in its booth (#501) at the 2022 Annual Meeting of the American Association of Hip and Knee Surgeons (AAHKS) from November 3-6 in Dallas, TX. 

Smith+Nephew will also showcase at AAHKS, its ‘Power Of One’ mobile exhibit – an interactive experience focused on the capabilities of handheld robotics and computer-guided surgery using the CORI Surgical System. It is small, portable, and does not require CT or MRI, making it a well-placed solution for hospitals, Ambulatory Surgical Centres, and Hospital Outpatient Departments.


1. Yayac M, Harrer S, Hozack WJ, Parvizi J, Courtney M. The use of cementless components does not significantly increase procedural costs in total knee arthroplasty. J Arthroplasty. 2020;35:407-712

2. Grieco TF, Sharma A, Dessinger GM, Cates HE, Komistek RD. In Vivo Kinematic Comparison of a Bicruciate Stabilized Total Knee Arthroplasty and the Normal Knee Using Fluoroscopy. J Arthroplasty. 2018;33(2):565-571. 

3. Iriuchishima T, Ryu K. A Comparision of Rollback Ratio between Bicruciate Substituting Total Knee Arthroplasty and Oxford Unicompartmental Knee Arthroplasty. J Knee Surg. 2018;31(6):568-572. 

4. Murakami K, Hamai S, Okazaki K, et al. Knee kinematics in bi-cruciate stabilized total knee arthroplasty during squatting and stair-climbing activities. J Orthop. 2018;15(2):650-654. 

5. Murakami K, Hamai S, Okazaki K, et al. In vivo kinematics of gait in posterior-stabilized and bicruciate-stabilized total knee arthroplasties using image-matching techniques. Int Orthop. 2018;42(11):2573-2581.

6. Smith LA, Nachtrab J, LaCour M, et al. In Vivo Knee Kinematics: How Important Are the Roles of Femoral Geometry and the Cruciate Ligaments? J Arthroplasty. 2021;36:1445-1454.

7. Carpenter RD, Brilhault J, Majumdar S, Ries MD. Magnetic resonance imaging of in vivo patellofemoral kinematics after total knee arthroplasty. Knee. 2009;16(5):332-336.

8. Catani F, Ensini A, Belvedere C, et al. In vivo kinematics and kinetics of a bi-cruciate substituting total knee arthroplasty: a combined fluoroscopic and gait analysis study. J Orthop Res. 2009;27(12):1569-1575

9. Moriarty P, Vles G, Haddad F, Konan S. Early clinical and radiological outcomes of a new tapered fluted titanium monobloc revision stem in hip arthroplasty. Act Orthop Trauma Surg. 2021;141:1065-1071. 

10. Smith+Nephew 2015. Orthopaedic Research Report OR-14-091A.

Technology for THA. Poster presented at: 2013 Annual Meeting of the Orthopaedic Research Society. Poster no. 1028. 

11. Papannagari R, Hines G, Sprague J, Morrison M. Long-term wear performance of an advanced bearing technology for TKA. Poster presented at: 2011 Annual Meeting of the Orthopaedic Research Society. Poster no. 1141.

12. DesJardins J, Burnikel B, LaBerge M. UHMWPE wear against roughened oxidized zirconium and CoCr femoral knee components during force-controlled simulation. Wear. 2008;264:245-256

13. Ries MD, Salehi A, Widding K, Hunter G. Polyethylene wear performance of oxidized zirconium and cobalt-chromium knee components under abrasive conditions. J Bone Joint Surg Am. 2002;84-A Suppl 2:129-135

*Clinical history based on Smith+Nephew’s REDAPT™ Revision Hip System

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit and follow us on TwitterLinkedInInstagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.

™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

SOURCE: Smith & Nephew plc

Image Credit: Smith & Nephew

Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button